Ads
related to: solid tumor cancer treatment
Search results
Evaluating CAR T-Cell Therapy Vascular Recruitment, Trafficking & Killing Efficacy With...
BioresearchOnline· 49 minutes agoIn the dynamic landscape of cancer treatment, chimeric antigen receptor (CAR) T cells have emerged...
Anti-Cancer Drug Pembrolizumab: Frequently Used Alone Or With Other Treatments
Forbes· 15 hours agoPembrolizumab, sold as Keytruda by Merck & Co., was one of the first inhibitors to hit the market. A...
FluoGuide Selects Laser System for Photothermal Cancer Therapy with FG001
Digital Journal· 6 hours agoFluoGuide's lead product, FG001 fluoresces and is designed to bind urokinase-type plasminogen activator receptor (uPAR) making it specific to cancer and with a potential for ...
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a...
CBS 47 Fresno· 3 days agoTyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been ...
TME Pharma Announces Convocation of the 2024 Annual General Meeting of Shareholders
Morningstar· 14 hours agoTME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME),a biotechnology company focused on developing novel therapies for treatment of cancer by targeting ...
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
FOX 23 News Albany· 6 days agoNovel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif., May 21, 2024 /PRNewswire/ -- Anixa Biosciences.
Nimbus reports positive data from Phase I/II solid tumour therapy trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe latest findings as of 18 March included data from 44 subjects in the dose...) achieved a...
Overcoming Resistance and Toxicity Hurdles: PST's Localized Drug Delivery Technology May Unlock...
WTRF Wheeling· 5 days agoPostsurgical Therapeutics, Inc. (PST) today announced the successful completion of an in vivo study of its proprietary injectable gel formulation containing two drugs used to treat several types ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...
SystImmune, Inc. Announces Transition of Chief Medical Officer
WTNH-TV New Haven· 4 days agoSystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for ...
Ad
related to: solid tumor cancer treatment
